RWD110 Real World Outcomes in Patients with Advanced/Metastatic Solid Tumors Who Are Immuno-Oncology (IO) Naive and Received Second-Line Therapy: Analysis by Tumor Mutational Burden (TMB) Status
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.2335
https://www.valueinhealthjournal.com/article/S1098-3015(22)04540-5/fulltext
Title :
RWD110 Real World Outcomes in Patients with Advanced/Metastatic Solid Tumors Who Are Immuno-Oncology (IO) Naive and Received Second-Line Therapy: Analysis by Tumor Mutational Burden (TMB) Status
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)04540-5&doi=10.1016/j.jval.2022.09.2335
First page :
Section Title :
Open access? :
No
Section Order :
11899